Recap: Adaptimmune Therapeutics Q1 Earnings

Shares of Adaptimmune Therapeutics ADAP rose 1.3% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were flat 0.00% year over year to ($0.04), which beat the estimate of ($0.25).

Revenue of $761,000 rose by 0.00% from the same period last year, which missed the estimate of $23,290,000.

Outlook

Adaptimmune Therapeutics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 14, 2020

Time: 08:02 PM ET

Webcast URL: https://edge.media-server.com/mmc/p/4772jrtc

Technicals

52-week high: $6.00

52-week low: $0.71

Price action over last quarter: Up 27.07%

Company Description

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.